Adela CaÃ±ete Nieto

List of Publications by Year
in descending order

78 papers	2,607 citations	236925 25 h-index	206112 48 g-index
82 all docs	82 docs citations	82 times ranked	3898 citing authors

#	Article	IF	Citations
1	Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries â€“ A study by the Joint Action on Rare Cancers. Cancer Epidemiology, 2022, 78, 102145.	1.9	0
2	MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 2022, 304, 174-182.	7.3	12
3	Germline variant in Ctcf links mental retardation to Wilms tumor predisposition. European Journal of Human Genetics, 2022, , .	2.8	1
4	Intratumoral immunosuppression profiles in 11qâ€deleted neuroblastomas provide new potential therapeutic targets. Molecular Oncology, 2021, 15, 364-380.	4.6	4
5	Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas. Journal of Personalized Medicine, 2021, 11, 268.	2.5	1
6	ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non-metastaticextremity high-grade osteosarcoma: A merged analysis of an Italian (ISG) and a Spanish (GEIS) sarcoma groups' multicentric prospective trials.. Journal of Clinical Oncology, 2021, 39, 11527-11527.	1.6	0
7	Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot study. Pediatric Blood and Cancer, 2021, 68, e29020.	1.5	7
8	MR Denoising Increases Radiomic Biomarker Precision and Reproducibility in Oncologic Imaging. Journal of Digital Imaging, 2021, 34, 1134-1145.	2.9	10
9	Retinoblastoma and mosaic 13q deletion: a case report. International Journal of Retina and Vitreous, 2021, 7, 50.	1.9	1
10	Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?. International Journal of Molecular Sciences, 2021, 22, 9815.	4.1	4
11	Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma. International Journal of Pharmaceutics, 2021, 608, 121058.	5.2	9
12	Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care. Cancers, 2021, 13, 5339.	3.7	7
13	Methodological advances in the discovery of novel neuroblastoma therapeutics. Expert Opinion on Drug Discovery, 2021, , 1-13.	5.0	5
14	Review: Ewing Sarcoma Predisposition. Pathology and Oncology Research, 2020, 26, 2057-2066.	1.9	11
15	Metabolomic profiling in neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28113.	1.5	5
16	Cancer in the first 18 months of life. Anales De PediatrÃa (English Edition), 2020, 93, 358-366.	0.2	0
17	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
18	PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers. European Radiology Experimental, 2020, 4, 22.	3.4	41

#	Article	IF	Citations
19	Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial. Clinical Cancer Research, 2020, 26, 1856-1865.	7.0	10
20	MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients. International Journal of Molecular Sciences, 2020, 21, 2714.	4.1	9
21	Low- and Intermediate-Risk Neuroblastoma. , 2020, , 205-212.		0
22	A Confidence Habitats Methodology in MR Quantitative Diffusion for the Classification of Neuroblastic Tumors. Cancers, 2020, 12, 3858.	3.7	6
23	Precision medicine in relapsed or refractory pediatric solid tumors: a collaborative Spanish initiative. Translational Medicine Communications, 2019, 4, .	1.4	2
24	Clinical Features of Neuroblastoma with 11q Deletion: An Increase in Relapse Probabilities in Localized and 4S Stages. Scientific Reports, 2019, 9, 13806.	3.3	15
25	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. Cancers, 2019, 11, 1476.	3.7	43
26	High Oct4 expression: implications in the pathogenesis of neuroblastic tumours. BMC Cancer, 2019, 19, 1.	2.6	420
27	Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma. BMC Cancer, 2019, 19, 479.	2.6	30
28	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2019, 66, e27819.	1.5	20
29	Eventâ€free survival of infants and toddlers enrolled in the HRâ€NBLâ€1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis. Pediatric Blood and Cancer, 2018, 65, e27052.	1.5	7
30	Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. Journal of Neuro-Oncology, 2018, 137, 205-213.	2.9	8
31	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. Journal of Clinical Oncology, 2018, 36, 951-958.	1.6	95
32	Risk stratification of highâ€risk metastatic neuroblastoma: A report from the HRâ€NBLâ€1/SIOPEN study. Pediatric Blood and Cancer, 2018, 65, e27363.	1.5	53
33	Advances in emerging drugs for the treatment of neuroblastoma. Expert Opinion on Emerging Drugs, 2017, 22, 63-75.	2.4	36
34	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 500-514.	10.7	256
35	Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition. Clinical Cancer Research, 2017, 23, 6875-6887.	7.0	34
36	Early clinical trials in paediatric oncology in Spain: A nationwide perspective. Anales De PediatrÃa (English Edition), 2017, 87, 155-163.	0.2	0

#	Article	IF	Citations
37	TIAM1 variants improve clinical outcome in neuroblastoma. Oncotarget, 2017, 8, 45286-45297.	1.8	15
38	HG-128BO25041 - A PHASE II OPEN-LABEL, RANDOMIZED, MULTI CENTRE COMPARATIVE STUDY OF BEVACIZUMAB BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR HIGH GRADE GLIOMA. Neuro-Oncology, 2016, 18, iii77.4-iii77.	1.2	1
39	HG-85INTER-OBSERVER AGREEMENT IN NEUROPATHOLOGICAL HGG DIAGNOSIS : EXPERIENCE OF THE PRE-RANDOMISATION CENTRAL REVIEW IN THE HERBY TRIAL. Neuro-Oncology, 2016, 18, iii68.1-iii68.	1.2	0
40	Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2016, 38, 176-181.	0.6	2
41	TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 573-580.	2.5	28
42	PNR-16DIAGNOSIS, MANAGEMENT AND OUTCOME OF CHILDREN WITH CENTRAL NERVOUS SYSTEM (CNS) PRIMITIVE NEUROECTODERMAL TUMORS (PNET) IN SPAIN: A STUDY FROM THE SPANISH NATIONAL PEDIATRIC ONCOLOGY & HEMATOLOGY SOCIETY (SEHOP). Neuro-Oncology, 2016, 18, iii9.5-iii10.	1.2	0
43	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. Journal of Neuroimmunology, 2016, 297, 98-102.	2.3	3
44	miRâ€200c and phosphoâ€AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis. Molecular Oncology, 2016, 10, 1043-1053.	4.6	44
45	Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2015, 37, e278-e284.	0.6	6
46	Presentation and Long-term Outcome of High-grade Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2015, 37, e272-e277.	0.6	8
47	Two independent epigenetic biomarkers predict survival in neuroblastoma. Clinical Epigenetics, 2015, 7, 16.	4.1	26
48	QUANTITATIVE APPROACH TO ASSIST NEUROBLASTOMA ASSESSMENT BY MEASURING I-123 mIBG UPTAKE IN SCINTIGRAPHIC IMAGES. Image Analysis and Stereology, 2015, 34, 135.	0.9	1
49	Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma. Pediatric Research, 2014, 75, 302-314.	2.3	17
50	Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration. Neoplasia, 2014, 16, 471-480.	5.3	25
51	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro-Oncology, 2013, 15, 1236-1243.	1.2	41
52	Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor. PLoS ONE, 2013, 8, e76761.	2.5	52
53	Pediatric Neuroblastoma: Use of Hypermethylation of Apoptotic Genes as a Prognostic Factor. Pediatric Cancer, 2013, , 3-10.	0.0	0
54	New prognostic markers in neuroblastoma. Expert Opinion on Medical Diagnostics, 2012, 6, 555-567.	1.6	7

#	Article	IF	Citations
55	Prognostic value of partial genetic instability in neuroblastoma with â‰¥50% neuroblastic cell content. Histopathology, 2011, 59, 22-30.	2.9	7
56	Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1263-1272.	2.5	19
57	Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Molecular Carcinogenesis, 2011, 50, 153-162.	2.7	39
58	Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1. Journal of Clinical Oncology, 2011, 29, 449-455.	1.6	101
59	Neuroblastoma in adolescents: genetic and clinical characterisation. Clinical and Translational Oncology, 2010, 12, 49-54.	2.4	28
60	Solid ovarian tumours in childhood: a 35-year review in a single institution. Clinical and Translational Oncology, 2010, 12, 287-291.	2.4	29
61	Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clinical and Translational Oncology, 2010, 12, 788-793.	2.4	20
62	Retained intravascular fragments after removal of indwelling central venous catheters: a single institution experience. Journal of Pediatric Surgery, 2010, 45, 1491-1495.	1.6	14
63	Poor Survival for Infants With MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. Journal of Clinical Oncology, 2009, 27, 1014-1019.	1.6	123
64	MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. Journal of Cancer Research and Clinical Oncology, 2009, 135, 523-531.	2.5	15
65	Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatric Blood and Cancer, 2009, 52, 209-214.	1.5	12
66	Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification. Journal of Clinical Oncology, 2009, 27, 1034-1040.	1.6	134
67	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	10.7	176
68	Congenital Fibrosarcoma Simulating Congenital Hemangioma. Pediatric Dermatology, 2008, 25, 141-144.	0.9	18
69	Immunohistochemical evaluation of a novel clone of monoclonal anti-MYCN antibody B8.4B in neuroblastic tumours: a correlation with MYCN gene status. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 277-278.	2.8	1
70	Tumour banks in pediatric oncology. Clinical and Translational Oncology, 2006, 8, 884-888.	2.4	7
71	The Doublecortin Gene, A New Molecular Marker to Detect Minimal Residual Disease in Neuroblastoma. Diagnostic Molecular Pathology, 2005, 14, 53-57.	2.1	41
72	A comparison of current neuroblastoma chemotherapeutics. Expert Opinion on Pharmacotherapy, 2004, 5, 71-80.	1.8	16

#	Article	IF	Citations
73	MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genetics and Cytogenetics, 2003, 140, 157-161.	1.0	30
74	Herpesvirus-6 Encephalitis Complicated by Wernickeâ€“Korsakoff Syndrome in a Pediatric Recipient of Unrelated Cord Blood Transplantation. The American Journal of Pediatric Hematology/oncology, 2001, 23, 626-628.	1.3	15
75	A Novel TP53 Germ-Line Mutation Identified in a Girl with a Primitive Neuroectodermal Tumor and Her Father. Cancer Genetics and Cytogenetics, 1998, 105, 103-108.	1.0	10
76	Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer, 1995, 75, 99-109.	4.1	159
77	Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 419-426.	2.1	20
78	Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. International Journal of Cancer, 1993, 54, 499-505.	5.1	48